Announcement • Aug 17
Suzhou Ribo Life Science Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026 Suzhou Ribo Life Science Co., Ltd. announced that they will report first half, 2026 results on Aug 27, 2026 Announcement • Jul 29
Suzhou Ribo Life Science Co., Ltd. Receives Approval To Initiate Phase 2b Clinical Trial Of Vortosiran For SPAF Suzhou Ribo Life Science Co., Ltd. announced that the European Medicines Agency (EMA) has granted approval to initiate the Phase 2b clinical trial ORBIT-XI-AF evaluating vortosiran (RBD4059), the world’s first and most advanced small interfering RNA (siRNA) therapy targeting Factor XI (FXI) for stroke prevention in patients with atrial fibrillation (SPAF). The authorization of the Phase 2b multi-regional clinical trial (MRCT) marks an important milestone for vortosiran and underscores the global development strategy for next-generation anticoagulant therapies. It also enables the Company to advance the program into the next stage of global clinical development. Vortosiran is a GalNAc-conjugated siRNA candidate based on the proprietary RiboGalSTAR™ liver-targeting platform. By selectively suppressing FXI synthesis, vortosiran inhibits the intrinsic coagulation pathway and delivers potent antithrombotic activity. Compelling human genetic evidence indicates that individuals with naturally reduced FXI levels are protected against thrombotic disease without a corresponding increase in spontaneous bleeding risk. Consequently, FXI inhibition has emerged as a highly attractive therapeutic approach with the potential to combine effective thrombosis prevention with an improved safety profile relative to existing anticoagulant therapies. Vortosiran may not ultimately be successfully developed and commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. Announcement • Jul 22
Suzhou Ribo Life Science Co., Ltd. Presents Positive Phase 2A Study Results of Core Product Vortosiran for Cad Suzhou Ribo Life Science Co., Ltd. presented the positive results from a Phase 2a study in Europe evaluating vortosiran (RBD4059), a small interfering RNA (siRNA) therapy targeting coagulation factor XI (FXI), in patients with chronic coronary artery disease (CAD) at the China Pharmaceutical Innovation Conference in Shanghai. The randomized, double-blind, placebo-controlled study demonstrated that vortosiran in patients receiving standard-of-care aspirin treatment was generally well tolerated and achieved profound, dose-dependent, and long-lasting suppression of FXI activity. The trial enrolled patients with chronic CAD and previous myocardial infarction who were on aspirin therapy. Patients completing the high-dose vortosiran dosing regimen, at a maintenance dose of 400 mg, achieved a mean maximum reduction in FXI activity of 92%, which was sustained for several months following dosing. These data support dosing intervals of every three to six months across various indications. The degree of FXI inhibition is markedly greater than that estimated for ongoing small molecule programs, which are typically dosed once or twice daily and are currently in Phase 3 clinical development. No treatment-related serious adverse events, major bleeding events, or clinically relevant non-major bleeding events were observed. These findings represent the first clinical proof-of-concept globally for siRNA-mediated FXI suppression in patients with CAD, supporting the potential of vortosiran as a differentiated, long-acting antithrombotic therapy. Vortosiran is a GalNAc-conjugated siRNA candidate based on the proprietary RiboGalSTAR™ liver-targeting platform. By selectively suppressing FXI synthesis, vortosiran inhibits the intrinsic coagulation pathway and delivers potent antithrombotic activity. Compelling human genetic evidence indicates that individuals with naturally reduced FXI levels are protected against thrombotic disease without a corresponding increase in spontaneous bleeding risk. Consequently, FXI inhibition has emerged as a highly attractive therapeutic approach with the potential to combine effective thrombosis prevention with an improved safety profile relative to existing anticoagulant therapies. Recent Insider Transactions • Jul 15
Key Executive recently bought HK$358k worth of stock On the 9th of July, Li-Ming Gan bought around 7k shares on-market at roughly HK$52.69 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Li-Ming has been a buyer over the last 12 months, purchasing a net total of HK$1.0m worth in shares. Recent Insider Transactions • Jul 09
Key Executive recently bought HK$331k worth of stock On the 30th of June, Li-Ming Gan bought around 7k shares on-market at roughly HK$45.97 per share. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Li-Ming has been a buyer over the last 12 months, purchasing a net total of HK$643k worth in shares. Live News • Jul 03
Suzhou Ribo Life Science Advances First siRNA Drug Candidate for MASH in Madrigal Collaboration Suzhou Ribo Life Science and Madrigal Pharmaceuticals have nominated their first siRNA candidate drug under a partnership targeting metabolic dysfunction-associated steatohepatitis (MASH), with IND-enabling studies now planned ahead of clinical trials.
The milestone marks concrete progress in Suzhou Ribo Life Science’s RNA therapeutics pipeline for liver diseases with high unmet medical need and moves the collaboration from discovery into formal preclinical development.
Suzhou Ribo Life Science shares last traded at HK$50.00, with the stock down 39.1% year to date, placing this pipeline update against a backdrop of recent share price pressure.
This milestone gives clearer visibility on the MASH program’s path toward human studies, but it also raises execution questions around regulatory progress, clinical trial design and eventual competitive positioning in a crowded metabolic liver disease field. Announcement • May 30
Suzhou Ribo Life Science and Ribocure Pharmaceuticals Submit Phase 2 Clinical Trial Application to EMA for RBD1119 Suzhou Ribo Life Science and Ribocure Pharmaceuticals announced the submission of Phase 2 Clinical Trial Application to the European Medicines Agency for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease. Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and venous thromboembolism, and has established an anticoagulation/antithrombotic pipeline. This new submission for coronary artery disease represents an important milestone in Ribo's program to advance innovative oligonucleotide-based therapies aimed at systematically addressing the root cause of thromboembolic diseases. Coronary artery disease remains a leading cause of morbidity and mortality globally, driven by atherosclerotic plaque formation and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard of care therapies, including antiplatelet and anticoagulant therapies, a substantial residual risk of thrombotic events remains in patients with stable coronary artery disease, even when treated with optimized treatment. Current therapies are further limited by an increased risk of bleeding, restricting their intensity and long-term use in many patients. Consequently, there is a significant unmet medical need for novel antithrombotic approaches that can provide effective and sustained protection against thrombosis while maintaining a favorable safety profile, particularly with respect to bleeding risk. Live News • May 30
Ribo Submits Phase 2 Trial Application for siRNA Coronary Therapy to European Regulator Suzhou Ribo Life Science and Ribocure Pharmaceuticals submitted a Phase 2 Clinical Trial Application to the European Medicines Agency for RBD1119, an siRNA-based therapeutic targeting coronary artery disease.
The filing advances the companies’ RNA-based pipeline in thromboembolic diseases, focusing on antithrombotic treatments that aim for improved safety and efficacy.
The move signals an effort to address unmet medical needs in coronary artery disease patients using siRNA therapeutics.
Progress into Phase 2 in Europe indicates a more clinically mature asset in Ribo’s portfolio and potentially broader geographic reach if the trial is cleared and initiated.
Investors may monitor EMA feedback, trial design details, and any early safety or efficacy readouts, as regulatory or clinical setbacks at this stage can materially affect development timelines and funding needs. Reported Earnings • Mar 26
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: CN¥2.11 loss per share (further deteriorated from CN¥2.10 loss in FY 2024). Revenue: CN¥148.5m (up 4.1% from FY 2024). Net loss: CN¥278.1m (loss widened 2.9% from FY 2024). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Hong Kong. Announcement • Mar 26
Suzhou Ribo Life Science Co., Ltd., Annual General Meeting, Jun 09, 2026 Suzhou Ribo Life Science Co., Ltd., Annual General Meeting, Jun 09, 2026. Location: f3, 3b-2 china resources life sciences park, tower 3, 16 baoshen south street, daxing, beijing China Announcement • Mar 20
Suzhou Ribo Life Science Co., Ltd. Expands with Ribopepstar Enabling Targeted Sirna Delivery to Multiple Organs Suzhou Ribo Life Science Co., Ltd. had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences. Following the success of RiboGalSTAR™, which has supported seven clinical programs and major global partnerships valued over USD 6,000 million, Ribo is now advancing its extra hepatic and multi-target platforms. The proprietary RiboPepSTAR™ technology enables precise siRNA delivery to key organs beyond the liver, with promising preclinical data across several tissues. Using RiboPepSTAR™, preclinical studies demonstrate selective uptake in proximal tubular cells across models, and up to 80% target gene knockdown (KD) has been achieved, from rodents to NHPs. Physiological proof of concept was further validated in several disease models, such as type 2 diabetes model, showing robust kidney specific target-related biomarker reduction. Ribo's first kidney-targeted drug has entered IND-enabling phase. A cardiac targeting conjugate resulted in sustained knockdown in heart using a mouse model. Minimal effects were observed in muscle and negligible activity in liver and kidney, confirming strong cardiac specificity. In NHPs, current delivery enabled potent and selective adipose targeting with 96% knockdown. Together, these results underscore RiboPepSTAR™'s potential to unlock siRNA-based therapies for renal, cardiac and metabolic diseases. In parallel, Ribo is advancing its multi target siRNA platform, enabling a single molecule to silence two or more genes simultaneously. Ribo's dual target siRNAs achieve knockdown levels comparable to single target molecules, enabling synergistic pathway modulation and enhanced therapeutic benefit with a single therapeutic entity. Ribo's proprietary extra hepatic and multi targeting platforms open the door to best-in-class therapies across a broad range of disease areas - fully aligned with Ribo's commitment to delivering next generation siRNA medicines to patients worldwide. Announcement • Mar 12
Suzhou Ribo Life Science Co., Ltd. to Report Fiscal Year 2025 Results on Mar 25, 2026 Suzhou Ribo Life Science Co., Ltd. announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026 New Risk • Feb 18
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 29% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 29% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CN¥425m net loss in 2 years). Announcement • Jan 23
Suzhou Ribo Life Science Co., Ltd. Announces Approval of Phase II Clinical Trial in China of RBD5044 Suzhou Ribo Life Science Co., Ltd. announced that the Group's self-developed RBD5044 Injection was approved for Phase II clinical trial from the National Medical Products Administration in China. RBD5044 is an APOC3-targeting siRNA. APOC3 is a protein synthesized almost exclusively in the liver that plays a critical role in lipid metabolism. RBD5044 addresses the complications associated with hypertriglyceridemia, making it a therapeutic option for managing lipid disorders. Announcement • Jan 09
Suzhou Ribo Life Science Co., Ltd. has completed an IPO in the amount of HKD 1.832455 billion. Suzhou Ribo Life Science Co., Ltd. has completed an IPO in the amount of HKD 1.832455 billion.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 2,748,800
Price\Range: HKD 57.97
Discount Per Security: HKD 1.7391
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 15,441,200
Price\Range: HKD 57.97
Discount Per Security: HKD 1.7391
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 13,420,400
Price\Range: HKD 57.97
Discount Per Security: HKD 1.7391
Transaction Features: Regulation S; Rule 144A; Sponsor Backed Offering Board Change • Jan 08
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Ruiping Wang was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
